A senior pharmaceuticals executive has called on the government to come up with a “proper” roadmap for raising spending on new medicines, saying Britain is “not a good place” to develop or sell drugs.

As dusk fell over East London, the brightly lit headquarters of Sanofi stood in stark contrast to the shadows looming over the UK’s pharmaceutical landscape. Inside, the atmosphere was palpable with concern. Paul Naish, the UK head of market access for the French drug giant, sat across from his team, grappling with the harsh realities of a declining investment climate. “We’ve still got the best universities, we’ve got some of the best scientists in the world, but it’s not a good place to do the development work for medicines,” he remarked, gravely assessing the situation. His words resonate as an urgent plea for a “proper roadmap” from the government regarding investment in new medicines—the very lifeblood of innovation in healthcare.

A Critical Inflection Point

The life sciences sector has long been touted as a crown jewel of the British economy, a beacon of potential and progress. However, recent developments have sparked alarm among stakeholders. Just this week, MSD (known as Merck in the U.S.) abandoned plans for a £1 billion research center in London, a move analysts deem a heavy blow to the industry. The closure highlights a troubling trend: multinational pharmaceutical companies are reconsidering their footprint in the UK market.

“This is symptomatic of a larger issue,” explains Dr. Harriet Wong, a senior researcher at the Cambridge Institute for Health. “When companies like MSD choose to retract their investments, it sends a clear message that the landscape is no longer favorable.” Naish’s assertion that Britain is at a “critical point” reverberates both within the industry and beyond.

Declining Clinical Trials and Rising Barriers

Sanofi has faced its own challenges, reportedly conducting 50% fewer clinical trials in the UK over the past two years. This decline stands in stark contrast to the company’s global investment of £35 million in R&D, out of a staggering £6.7 billion worldwide. The disconnect raises questions about the UK’s viability as a hub for innovative drug development.

Furthermore, Naish cited the NHS’s dwindling spending on medicines, now accounting for only 9% of total healthcare expenditures, compared to 14% in Germany and 15% in the U.S. This comparative figure underlines a crucial gap in financial support for drug innovation.

• Medicines spending as a percentage of total healthcare spending:
• Germany: 14%
• United States: 15%
• Italy: 17%
• Spain: 17%
• United Kingdom: 9%

Moreover, the price thresholds set by the National Institute for Health and Care Excellence (NICE) have remained stagnant since 1999. This lack of adjustment renders the UK market less attractive for companies that rely on competitive pricing to recoup the costs of research and development.

The Internal Struggle

Naish articulated a “battle happening within government,” observing that health department officials often struggle to persuade the Treasury for reconsideration of pharmaceutical funding. “There needs to be a proper plan from Treasury, sat down with the other departments, for what raising the spend to be more in line with other countries looks like,” he emphasized. His call to action resonates with industry leaders such as Tom Keith-Roach, AstraZeneca’s UK president, who expressed similar sentiments about the necessity for an updated threshold in line with inflation.

“Without a commitment to change, the industry will continue to drift away,” warns Professor Julian West, an economics expert at London School of Economics. “It’s not just about funding; it’s about creating an ecosystem where innovation can thrive.” His observations underline the urgent need for strategic collaboration between multiple government departments to secure the future of pharmaceutical innovation in the UK.

Industry Reactions

The stark realities facing pharmaceutical companies have triggered a robust discussion about cost structures. Industry advocates argue for a reduction in clawback rates, which currently require drugmakers to pay back to the NHS between 25% and 33% of their revenues. They propose simplifying this complex financial obligation to single digits, thereby aligning it with levels seen in other European countries.

Amidst these discussions, reports suggest that officials in the Department of Health and Social Care (DHSC) are attempting to restart negotiations with pharmaceutical companies regarding drug pricing. However, this effort follows a recent rejection of Health Secretary Wes Streeting’s ultimatum regarding NHS pricing strategies. The situation remains fluid, and the stakes are high.

The Future of Pharmaceutical Innovation

Prominent figures like Sir John Bell, a formidable scientist and former Regius Professor at the University of Oxford, have expressed warning signals regarding the future of investment in the UK. “Conversations with CEOs from leading pharmaceutical companies suggest that many are contemplating a retreat from British shores,” he cautioned during a recent forum. Eli Lilly’s decision to place its planned London gateway lab on hold exemplifies this trend of hesitancy. The company has established multiple labs in the U.S. and China, showcasing a shift in focus that reflects a lack of confidence in the UK’s competitive landscape.

As discussions unfold, the repercussions for patients, healthcare practitioners, and the economy are immense. The pharmaceutical industry stands at a crossroads, and a cohesive, proactive strategy is essential to regenerate its stature on the global stage. The UK still possesses unique assets—world-class researchers, pioneering universities, and the historical legacy of pharmaceutical innovation—but without concerted governmental effort and industry collaboration, these advantages may fade into obscurity.

Source: www.theguardian.com